Suggested remit: To appraise the clinical and cost effectiveness of darolutamide with androgen deprivation therapy within its marketing authorisation for treating hormone-sensitive metastatic prostate cancer.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- Cost Comparison Standard
- ID number:
- 6452
Provisional Schedule
- Expected publication:
- 11 September 2025
Project Team
- Project lead
- Vonda Murray
Email enquiries
If you have any queries please email [email protected]
Stakeholders
- Companies sponsors
- Bayer (darolutamide)
- Others
- Department of Health and Social Care
- Health Technology Wales
- NHS England
- Patient carer groups
- Prostate Cancer UK
- Tackle Prostate Cancer
- Professional groups
- Association of Cancer Physicians
- British Uro-Oncology Group
- Cancer Research UK
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Comparator companies
- Accord (bicalutamide, docetaxel, relugolix)
- Astellas Pharma (enzalutamide)
- AstraZeneca (bicalutamide, goserelin)
- Ipsen (triptorelin)
- Johnson and Johnson Innovative Medicine (apalutamide)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 19 March 2025 | Invitation to participate |
| 12 December 2024 | Referral |
| 08 November 2024 - 06 December 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6452 |
| 08 November 2024 | In progress. Scoping commencing |
| 30 May 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 30 May 2024 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual